Dyne Therapeutics, Inc. (DYN) Stock Forecast
DYN analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.65 / 5 from 17 analysts
- Price target
- $35.73 average of analyst targets
- Upside to target
- +150.8% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.88
- 52-week range
- $14.25 – $26.78
DYN analyst ratings
17 analystsNumber of analysts at each rating.
DYN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
DYN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.89 | −$1.09 | −$0.72 | −$0.76 | −16.8% | 14 |
| Current fiscal year (2026) | −$3.55 | −$3.94 | −$2.94 | −$3.47 | −2.3% | 15 |
| Next fiscal year (2027) | −$3.34 | −$4.53 | −$2.79 | −$3.55 | +6.0% | 13 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
DYN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 15 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 16 |
| Next fiscal year (2027) | $52.8M | $0 | $198.8M | 0.0% | 15 |
DYN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
DYN revenue: reported and forecast
DYN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.77 | −$0.87 | −$0.89 | −$0.89 | −$0.89 | +16.0% | 1 up · 1 down |
| Current fiscal year (2026) | −$3.09 | −$3.55 | −$3.55 | −$3.55 | −$3.55 | +14.8% | 1 up · 0 down |
| Next fiscal year (2027) | −$3.00 | −$3.26 | −$3.33 | −$3.34 | −$3.34 | +11.3% | 3 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
DYN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; DYN beat in 5 of 12.
What analysts expect from DYN
17 analysts cover Dyne Therapeutics; their consensus rating is strong buy (4.65 on a 1–5 scale, where 5 is a strong buy). The average price target is $35.73, 150.8% above the latest close of $14.25. Analysts expect earnings of −$3.55 per share for 2026, −2.3% from a year earlier. For 2027 the average estimate is −$3.34 per share on revenue of $52.8 million. Dyne Therapeutics beat the EPS estimate in 5 of the last 12 quarters.
Related: DYN income statement, DYN key metrics, DYN chart. See the DYN stock overview for the latest quote and news.
DYN forecast FAQ
What is Dyne Therapeutics's price target?
The average analyst price target for Dyne Therapeutics is $35.73, 150.8% above the latest close of $14.25.
Is Dyne Therapeutics a buy, hold or sell?
Of 17 analysts covering Dyne Therapeutics, 13 rate it a strong buy, 3 a buy, 0 a hold, 1 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Dyne Therapeutics's EPS forecast?
Analysts forecast −$3.55 per share for 2026 (range −$3.94 to −$2.94); for 2027 the estimate is −$3.34.
When does Dyne Therapeutics report earnings?
Dyne Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-0.88.
Does Dyne Therapeutics usually beat earnings estimates?
Dyne Therapeutics reported EPS at or above the analyst estimate in 5 of the last 12 quarters.